Literature DB >> 15681167

Truncated deoxynivalenol-induced splenic immediate early gene response in mice consuming (n-3) polyunsaturated fatty acids.

Shawn Kinser1, Maioxing Li, Qunshan Jia, James J Pestka.   

Abstract

Expression profiling has previously revealed that acute exposure to the common foodborne mycotoxin deoxynivalenol (DON) induces a large number of immediate early genes in murine lymphoid tissues that potentially affect immune function. The purpose of this study was to test the hypothesis that consumption of (n-3) polyunsaturated fatty acids (PUFAs) found in fish oil interferes with DON-induced immediate early gene expression. Mice were fed AIN-93G diet containing 1% corn oil (CO) plus 6% oleic acid (control) or a diet containing 1% CO, 2% fish oil enriched in the (n-3)-PUFAs docosahexaenoic and eicosapentaenoic acid and 4% oleic acid. After 12 weeks, the mice were gavaged orally with 25 mg/kg DON and the kinetics of immediate early gene expression in spleen monitored over 8 h by real-time polymerase chain reaction (PCR). Deoxynivalenol was found to readily induce expression of cytokines (IL-1alpha, IL-1beta, and IL-6 and IL-11), chemokines (MCP-1, MCP-3, CINC-1 and MIP-2), components of the activator protein-1 (AP-1) transcription factor complex (c-Fos, Fra-2, c-Jun and JunB), as well as two hydrolases (MKP1, CnAbeta). Expression of these genes was transient, peaking within 2-4 h and declining thereafter, with the single exception being IL-11 that was elevated at 8 h. (n-3)-PUFA consumption significantly suppressed DON-induced expression of IL-1alpha, IL-6, IL-11, MCP-1, MCP-3, MIP-2 and Fra-2 at 8 h. In contrast, mice fed (n-3)-PUFA exhibited significant increases in MKP1 and CnAbeta expression. Taken together, these data suggest that dietary supplementation with (n-3)-PUFAs prematurely truncated cytokine, chemokine and transcription factor expression responses to DON that may impact its previously described capacity to disrupt immune function including immunoglobulin A (IgA) production. Since expression of many of these genes has been linked to mitogen-activated protein kinase (MAPK) activation, enhanced expression of MKP1, a negative MAPK regulator in (n-3)-PUFA-fed mice might contribute to this suppression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15681167     DOI: 10.1016/j.jnutbio.2004.10.003

Source DB:  PubMed          Journal:  J Nutr Biochem        ISSN: 0955-2863            Impact factor:   6.048


  6 in total

1.  Activation of liver X receptor (LXR) inhibits receptor activator of nuclear factor κB ligand (RANKL)-induced osteoclast differentiation in an LXRβ-dependent mechanism.

Authors:  Kirsten M Robertson Remen; Petra Henning; Ulf H Lerner; Jan-Åke Gustafsson; Göran Andersson
Journal:  J Biol Chem       Date:  2011-07-22       Impact factor: 5.157

2.  Deoxynivalenol and its toxicity.

Authors:  Pavlina Sobrova; Vojtech Adam; Anna Vasatkova; Miroslava Beklova; Ladislav Zeman; Rene Kizek
Journal:  Interdiscip Toxicol       Date:  2010-09

3.  Modulation of inflammatory gene expression by the ribotoxin deoxynivalenol involves coordinate regulation of the transcriptome and translatome.

Authors:  Kaiyu He; Xiao Pan; Hui-Ren Zhou; James J Pestka
Journal:  Toxicol Sci       Date:  2012-09-11       Impact factor: 4.849

4.  Global protein phosphorylation dynamics during deoxynivalenol-induced ribotoxic stress response in the macrophage.

Authors:  Xiao Pan; Douglas A Whitten; Ming Wu; Christina Chan; Curtis G Wilkerson; James J Pestka
Journal:  Toxicol Appl Pharmacol       Date:  2013-01-23       Impact factor: 4.219

5.  Comparative induction of 28S ribosomal RNA cleavage by ricin and the trichothecenes deoxynivalenol and T-2 toxin in the macrophage.

Authors:  Maoxiang Li; James J Pestka
Journal:  Toxicol Sci       Date:  2008-06-04       Impact factor: 4.849

Review 6.  Deoxynivalenol-induced proinflammatory gene expression: mechanisms and pathological sequelae.

Authors:  James J Pestka
Journal:  Toxins (Basel)       Date:  2010-06-01       Impact factor: 4.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.